The Aperlena Verdict
Open raceNo supplier dominates: 30 different companies have won the last 35 comparable contracts from this buyer over 5 years. This is a genuinely open race.
Based on 35 comparable awards by this buyer in this sector over 5 years. Every verdict is recorded before the outcome and graded against the award notice. How we score ourselves.
Summary
Machine-generated summaryGWQ ServicePlus AG, acting for its shareholder and customer health insurance funds, is concluding non-exclusive discount agreements with pharmaceutical companies under § 130a para. 8 SGB V for a specific active substance, starting 01.09.2026. Any interested company may join at any time during the contract term on identical terms (admission model). GWQ considers the procedure outside German public procurement law since there is no selection decision. Contract documents, participating funds and reporting deadlines are available on the GWQ award portal. Signed contracts plus required proof should be submitted by 10.08.2026 so first reporting can occur on 01.09.2026. Place: Germany.
Description
Can I bid?
- Open procedure: any interested supplier may submit a bid. Above the EU threshold: open to companies from any EU country.
- The notice is written in German.
- Certificates from another EU country? Check the equivalents on eCertis
Official source
Source: TED - Tenders Electronic Daily (Publications Office of the EU)
Always verify details on the official notice.
Report an error in this notice
Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 1 month ago
More from this buyer
Full buyer profile20 open tenders right now
- Medicines - Conclusion of non-exclusive discount agreements under Section 130a (8) SGB V from 01.02.2026 71 days left
- Medicines - Conclusion of non-exclusive discount agreements under § 130a para. 8 SGB V for the active ingredient Budesonide in the dosage form HKM 222 days left
- Pharmaceuticals - Conclusion of a non-exclusive discount agreement under § 130a para. 8 SGB V for patent-protected active substances - VV90 314 days left
Who usually wins this buyer's contracts in this sector
| Company | Wins | Total awarded | Last win |
|---|---|---|---|
| APONTIS PHARMA Deutschland GmbH & Co. KG | 2 | n/a | Sep 2026 |
| Galenpharma GmbH; Zentiva Pharma GmbH; Aristo Pharma GmbH; Theramex Ireland Limited; Hexal AG; ratiopharm GmbH; BG ALIUD / STADAPHARM GbR; Micro Labs GmbH; BG Heumann / Heunet GbR; ROVI GmbH; Venipharm GmbH; PUREN Pharma GmbH & Co. KG; Bayer Vital GmbH; neuraxpharm Arzneimittel GmbH; Hormosan Pharma | 2 | n/a | Aug 2026 |
| LEO Pharma GmbH | 2 | n/a | May 2026 |
| neuraxpharm Arzneimittel GmbH | 2 | n/a | Mar 2026 |
| Novartis Pharma GmbH | 2 | n/a | May 2026 |
Based on 35 awards with a linked company profile over the last 5 years.
What this buyer has paid before
Based on 22 comparable contracts this buyer awarded in this sector over the last 4 years.
- Lower quartile
- €1
- Median award
- €1
- Upper quartile
- €1
Most recent awards
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 a Abs. 8 SGB V zu dem Präparat mit dem Wirkstoff Efbemalenograstim alfa (Ryzneuta)
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 c SGB V zu dem Präparat mit dem Wirkstoff Galcanezumab (Emgality)
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 c SGB V zu dem Präparat mit dem Wirkstoff Edoxaban (Lixiana)
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 a Abs. 8 SGB V und §130 c SGB V zu den Präparat mit dem Wirkstoff Depemokimab
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 c SGB V zu dem Präparat Dolutegravir (Tivicay)
Award values as published by the official sources. Use them as a guide, not a rule: scope, lots and duration differ between contracts.
Change history
Every time an official source republished this notice with different content. We watch every source we index, including regional copies of the same notice.
-
Act now
- Submission deadline: Brought forward by 1 day: now May 10, 2028, 00:00
- Scope and criteria: The description was expanded. Re-read it before you bid.
Follow this tender and we email you the moment it changes. Create account
Similar tenders
Market context
- Avg. open tender · Medical equipment & pharmaceuticals
- €11,290,021
- Buyer track record on Aperlena
- 62 notices tracked · 35 awarded
- €22 in awarded contracts
Never miss a tender like this
71 new notices in Medical equipment & pharmaceuticals in Germany in the last 7 days. Get an email when new ones appear. Free.
Set up my alert